436 related articles for article (PubMed ID: 31502008)
21. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
[TBL] [Abstract][Full Text] [Related]
22. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
23. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
24. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
[TBL] [Abstract][Full Text] [Related]
25. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
26. Genetically modified immune cells for cancer immunotherapy.
Jiang L; Wang W
Sci China Life Sci; 2018 Oct; 61(10):1277-1279. PubMed ID: 30276708
[No Abstract] [Full Text] [Related]
27. Leveraging natural killer cells for cancer immunotherapy.
Grossenbacher SK; Aguilar EG; Murphy WJ
Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
[TBL] [Abstract][Full Text] [Related]
28. Infusions of allogeneic natural killer cells as cancer therapy.
Leung W
Clin Cancer Res; 2014 Jul; 20(13):3390-400. PubMed ID: 24987108
[TBL] [Abstract][Full Text] [Related]
29. NK-92 cell, another ideal carrier for chimeric antigen receptor.
Wang WN; Zhou GY; Zhang WL
Immunotherapy; 2017 Aug; 9(9):753-765. PubMed ID: 28771105
[TBL] [Abstract][Full Text] [Related]
30. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
31. The biology of natural killer cells and implications for therapy of human disease.
Chiorean EG; Miller JS
J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
[TBL] [Abstract][Full Text] [Related]
32. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.
Arina A; Murillo O; Dubrot J; Azpilikueta A; Alfaro C; Pérez-Gracia JL; Bendandi M; Palencia B; Hervás-Stubbs S; Melero I
Expert Opin Biol Ther; 2007 May; 7(5):599-615. PubMed ID: 17477799
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
34. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapeutic potential of NK and NKT cell lines in hematopoietic malignancies.
Hu Z
Leuk Res; 2003 Oct; 27(10):879-81. PubMed ID: 12860005
[No Abstract] [Full Text] [Related]
37. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.
Haeryfar SM
Arch Iran Med; 2008 Mar; 11(2):186-95. PubMed ID: 18298297
[TBL] [Abstract][Full Text] [Related]
38. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
39. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
40. IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
Pilipow K; Roberto A; Roederer M; Waldmann TA; Mavilio D; Lugli E
Cancer Res; 2015 Dec; 75(24):5187-5193. PubMed ID: 26627006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]